Fepixnebart

非奈拜单抗

Report date: 2023/03/16 14:45:41

Base Information

Drug NameFepixnebart
Drug Alias NameLY-3016859
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTransforming growth factor alpha inhibitorsEpiregulin inhibitors
TargetsEpiregulinTransforming growth factor alpha
Therapy Area/IndicationsLow Back PainDiabetic NephropathiesDiabetic Neuropathies +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPuerto Rico +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsLow Back PainDiabetic NeuropathiesOsteoarthritis, Knee +[4] 
Inactive IndicationsDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A